ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

In Brief: Lane Adams Retires, Gadberry New Executive VP; Lemaistre ACS President, Loeb President Elect

November 15, 1985

Senate Committee Approves Additional $400 Million For NCI, $275 Million For FDA.

May 16, 2008

Funding opportunities listed.

June 4, 2004

Major New Grant Programs Approved In Carcinogenesis, Chemoprevention

May 9, 1980

DCPC Advisors Okay New Grant Programs To Improve Participation Of Women, Minorities In Clinical Trials

May 26, 1995

In Brief: Gramm-Rudman-Hollings Could Slash NCI Budget By $650 Million; Holleb Retires From ‘Ca’

July 27, 1990